Stock listing

NASDAQ:BIOA BioAge Labs, Inc. Stock

Home listing (NASDAQ) of BioAge Labs, Inc.

Follow BioAge Labs, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BIOA

$4.28 USD -0.49 (-10.3%)

Close on Nov 20, 2026

Past year -50.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.24 – $4.77 USDNov 20, 2026
Volume
632,102 sharesNov 20, 2026
Market cap
$196.4M USDAt the close on Nov 20, 2026 · price × 45.90M shares outstanding
52-week range
$4.24 – $25.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$5.05M USDMedian day 643,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BioAge Labs, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BIOA · Home$4.28 USD-0.49 (-10.3%)632,102$4.60$4.77$4.235$4.77Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BIOA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.28-0.49-10.3%$4.60$4.77$4.235632,102
$4.77-0.33-6.5%$5.13$5.13$4.77640,564
$5.10-0.12-2.3%$5.305$5.305$4.98481,159
$5.22-0.33-5.9%$5.50$5.64$5.08689,013
$5.55-0.10-1.8%$5.71$5.71$5.39427,402
$5.65-0.22-3.7%$5.735$5.869$5.47471,444
$5.87+0.09+1.6%$5.83$6.08$5.755434,958
$5.78+0.09+1.6%$5.62$5.90$5.54490,739
$5.69+0.35+6.6%$5.36$5.74$5.16829,135
$5.34-0.20-3.6%$5.31$5.51$5.24683,436
$5.54-0.41-6.9%$5.93$6.02$5.46672,198
$5.95-0.01-0.2%$6.03$6.30$5.74613,069
$5.96+0.16+2.8%$5.83$6.01$5.58860,031
$5.80-0.07-1.2%$6.00$6.02$5.54688,852
$5.87-0.07-1.2%$5.86$5.925$5.63800,727
$5.940.000.0%$5.95$6.255$5.82845,300
$5.94+0.47+8.6%$5.41$5.97$5.221,434,900
$5.47+0.48+9.6%$4.98$5.51$4.921,108,000
$4.99-0.11-2.2%$5.10$5.15$4.92539,000
$5.10-0.43-7.8%$5.48$5.48$5.05464,200
$5.53+0.02+0.4%$5.45$5.62$5.411482,300
$5.51-0.05-0.9%$5.61$5.70$5.43568,500
$5.56+0.57+11.4%$5.00$5.64$4.971,204,600
$4.99+0.15+3.1%$4.84$5.11$4.821,245,200
$4.84-0.51-9.5%$5.35$5.35$4.81868,100
$5.35-0.07-1.3%$5.48$5.50$5.28811,300
$5.42-0.15-2.7%$5.49$5.58$5.36614,900
$5.57-0.37-6.2%$5.90$5.90$5.54638,500
$5.94-0.40-6.3%$6.24$6.295$5.875482,000
$6.34+0.13+2.1%$6.21$6.47$6.145667,300
$6.21-0.05-0.8%$6.17$6.265$5.99906,900
$6.26-0.03-0.5%$6.23$6.675$6.17799,500
$6.29-0.07-1.1%$6.44$6.45$6.003,251,700
$6.36-0.25-3.8%$6.65$6.65$6.25781,200
$6.61-0.20-2.9%$6.92$6.92$6.47869,600
$6.81-0.28-3.9%$7.06$7.17$6.70591,100
$7.09-0.05-0.7%$7.20$7.26$6.97755,200
$7.14-0.04-0.6%$7.19$7.27$7.07424,900
$7.18+0.13+1.8%$7.11$7.425$6.96800,100
$7.05-0.16-2.2%$7.26$7.295$7.03630,300
$7.21-0.68-8.6%$7.79$7.88$7.191,010,900
$7.89-0.57-6.7%$8.43$8.49$7.68618,500
$8.46+0.37+4.6%$8.20$8.53$8.111,067,400
$8.09+0.03+0.4%$8.07$8.10$7.73787,000
$8.06-0.03-0.4%$8.07$8.23$7.861,509,000
$8.09+0.34+4.4%$7.85$8.36$7.70940,100
$7.75-0.43-5.3%$8.21$8.275$7.62715,800
$8.18-0.30-3.5%$8.48$8.50$8.02643,500
$8.48-0.01-0.1%$8.52$8.635$8.39563,400
$8.49-0.16-1.8%$8.71$8.89$8.28672,100
$8.65-0.52-5.7%$9.07$9.07$8.60492,700
$9.17-0.225-2.4%$9.38$9.40$9.02488,300
$9.395-0.195-2.0%$9.60$9.645$9.324388,000
$9.59+0.09+0.9%$9.39$9.76$9.39314,500
$9.50-0.23-2.4%$9.90$9.98$9.415407,300
$9.73+0.21+2.2%$9.59$10.05$9.425541,300
$9.52+0.02+0.2%$9.28$9.72$9.15605,000
$9.50-0.15-1.6%$9.61$9.63$9.201,032,100
$9.65-0.43-4.3%$10.06$10.25$9.595452,200
$10.08+0.24+2.4%$9.93$10.23$9.80475,300
$9.84-0.27-2.7%$10.03$10.03$9.76503,900
$10.11+0.73+7.8%$9.55$10.13$9.55498,300
$9.38-0.10-1.1%$9.57$9.65$9.16658,900
$9.48-0.21-2.2%$9.78$9.916$9.48453,400
$9.69-1.06-9.9%$10.64$10.73$9.63776,800
Ticker
NASDAQ:BIOA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All BioAge Labs, Inc. news

BioAge Labs, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 42 in all · newest Nov 11, 2026 · oldest 2024
Decks
2 decks · latest September 2026

Where BioAge Labs, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BIOA · Home listing · This pageNASDAQUnited StatesUSD
gettex:Y7GgettexGermanyEUR
Lang & Schwarz:A40D7PLang & SchwarzGermanyEUR
BOATS:BIOABOATSUnited StatesUSD
Tradegate:Y7GTradegateGermanyEUR
LS Exchange:A40D7PLS ExchangeGermanyEUR
Frankfurt:Y7GFrankfurtGermanyEUR
Dusseldorf:Y7GDusseldorfGermanyEUR
Hamburg:Y7GHamburgGermanyEUR
Munich:Y7GMunichGermanyEUR
Stuttgart:Y7GStuttgartGermanyEUR

Valuation

EV/sales −10.1× against a median of 9.8×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$87.20M USD
P/E
Loss
EV/sales
−10.1×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
2.06

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioAge Labs, Inc. · NASDAQ:BIOAUS$196.4M−US$87.20Mn/a−10.1×n/a0.6×n/a0.0×2.06
Hightide Therapeutics Inc · HKEX:2511US$204.6MUS$178.9Mn/an/an/a8.2×n/a0.9×n/a
PharmaEngine, Inc. · TPEX:4162US$204.2MUS$50.36M12.5×1.6×3.4×1.4×52.6%0.0×n/a
Cabaletta Bio, Inc. · NASDAQ:CABAUS$201.9M−US$97.45Mn/an/an/a0.7×n/a0.0×1.89
Bright Minds Biosciences Inc. · CSE:DRUGUS$199.5M−US$15.18Mn/an/an/a0.9×n/a0.0×0.32
Newron Pharmaceuticals S.p.A. · SIX:NWRNUS$199.5MUS$206.2Mn/a9.8×n/an/a−69.2%n/an/a
NervGen Pharma Corp. · NASDAQ:NGENUS$198.4MUS$137.8Mn/an/an/a16.4×n/a0.0×1.46
Lineage Cell Therapeutics, Inc. · AMEX:LCTXUS$195.3MUS$152.1M111×14.0×n/a2.9×16.2%0.0×1.33
AC Immune SA · NASDAQ:ACIUUS$193.9MUS$110.5Mn/a4.7×n/a6.0×−181.9%0.1×1.56
SillaJen, Inc. · KRX:215600US$193.5MUS$141.7Mn/a17.6×n/a2.6×−223.8%0.0×n/a
AN2 Therapeutics, Inc. · NASDAQ:ANTXUS$192.8MUS$128.4Mn/an/an/a2.5×n/a0.0×0.54
Median of the othersUS$198.9MUS$133.1M61.9×9.8×3.4×2.6×−69.2%0.0×1.40

Forecasts

5 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
28.44 USD · Analysts' mean
EPS, year to Dec 2026
-2.61 · 8 analysts
Revenue, year to Dec 2026
6.81M · 11 analysts

Team and board

Officers

OfficerRole
Kristen FortneyCo-Founder, CEO
Dov GoldsteinChief Financial Officer
Eric MorgenCo-Founder, COO
Chris PatilVP, Media
George HartmanSVP, Chemistry
Joseph RodgersVP, Discovery Research
Julie GammelgardSVP, People
Kevin WilhelmsenVP, Biology
Naisha ShahSVP, Data Science
Nancy Mitchell-SweeneyVP & Head of Clinical Operations
Patrick MartinSVP, Clinical Science
Paul RubinCMO & EVP, Research
Rusty MontgomerySVP, Research
Sangita GhoshSVP, Technical Operations
Shane BartonSVP, Finance
Yan WangSVP, Translational Aging Biology
Yvonne Van GesselVP, Nonclinical Development
Ann NealeChief Development Officer
BJ SullivanChief Strategy Officer
Peng LeongChief Business Officer & Therapeutic Area Head, Brain Aging
Vijay PandeCo-founder & Managing Partner, VZVC

Board

DirectorRole
Jean-Pierre GarnierChair of the Board
Michael DavidsonIndependent Director
Rekha HemrajaniIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close−3.6%
Q2 2026Aug 5, 2026 · After close+2.6%
Q1 2026May 8, 2026 · Before open+0.9%
Q4 2025Mar 19, 2026−0.3%
Q3 2025Nov 6, 2025 · After close−2.8%
Q2 2025Aug 6, 2025 · After close−0.2%
Q1 2025May 6, 2025 · After close+2.8%
Q4 2024Mar 20, 2025+1.1%
Q3 2024Nov 7, 2024 · After close+7.6%
Q2 2024Aug 28, 2024

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck61 slidesSeptember 2026
Investor Day (May 2026)Investor day106 slidesMay 8, 2026

Open Decks

Financings

RaiseDate
Public offering of shares of common stock
Made bigger: about US$115M · US$19.5 a share · Goldman Sachs & Co. LLC +2
Dealers: Goldman Sachs & Co. LLC (co-lead), Piper Sandler (co-lead), Citigroup (co-lead)
Use of proceeds: R&D, clinical and manufacturing of product candidates incl. BGE-102, NLRP3 and APJ programs; working capital, capex, debt reduction, general corporate purposes
Jan 22, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Sep 25, 2024.

Price
US$18.00 a share
Shares offered
11,000,000 shares of common stock
Offering size
US$198 million
Underwriters' option
Up to 1,650,000 more shares
Underwriters
Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Citigroup · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 31, 2024
Filed publiclySep 3, 2024
Amended twiceNewest Sep 25, 2024
Shares registered with an exchangeSep 18, 2024
Declared effective by the SECSep 25, 2024
Final prospectus, with the priceSep 26, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Sep 26, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014FY2013
Revenue8.99M00014.9M8.27M2.17M1.54M2.67M
Cost of revenue213.0K22.3M13.7M2.61M6.04M2.69M
Gross profit8.99M-7.38M-5.39M-440.8K-4.50M-23.8K
Research and development74.0M59.0M33.9M30.5M5.47M7.20M20.3M15.2M16.6M
Selling, general and administrative27.8M19.2M14.5M9.45M10.4M6.54M6.59M6.17M5.03M
Operating income-92.8M-78.2M-48.4M-40.0M-110.0M-29.6M-38.5M-35.2M-41.2M
Depreciation and amortization200.0K200.0K200.0K129.0K9.35M9.16M4.16M1.37M1.71M
EBITDA-92.6M-78.0M-48.2M-39.8M-100.7M-20.5M-34.4M-33.8M-39.5M
Interest expense697.0K2.37M7.79M241.0K7.43M
Income before tax-80.6M-71.1M-63.9M-39.7M-102.1M-28.3M-41.2M-47.2M-33.7M
Income tax000241.0K81.7K25.6K-3.79K75.4K102.8K
Net income-80.6M-71.1M-63.9M-39.7M-98.2M-22.5M-37.2M-46.4M-33.2M
Earnings per share, basic-2.24-6.63-38.17-1.16-2.34-0.66-1.32-1.65-1.18
Earnings per share, diluted-2.24-6.63-38.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014FY2013
Cash and equivalents188.9M354.3M21.6M27.6M4.63M16.2M6.97M51.0M83.7M
Short-term investments92.2M0
Receivables769.0K04.86M986.9K978.6K476.9K755.0K
Inventory4.82M4.50M1.75M1.80M2.42M
Current assets286.8M357.1M25.3M28.0M15.2M31.4M10.8M57.1M95.0M
Property, plant and equipment963.0K591.0K323.0K
Goodwill625.4K625.4K625.4K692.8K
Total assets294.9M358.2M25.9M28.4M69.5M161.3M143.1M152.4M114.1M
Accounts payable2.67M2.00M1.87M2.26M6.15M6.02M15.8M983.5K29.5K
Current liabilities20.1M27.8M58.2M5.86M11.3M45.3M29.7M22.9M17.8M
Long-term debt02.50M8.20M2.25M
Total debt2.65M8.50M14.2M2.47M37.6M52.3M40.1M37.6M29.7M
Total liabilities22.8M35.1M66.6M141.0M47.7M112.8M96.7M94.9M49.1M
Shareholders' equity272.1M323.1M-173.4M-112.6M21.9M48.5M46.4M57.5M65.0M
Shares outstanding37.4M35.9M1.67M34.2M41.9M34.2M28.2M28.2M28.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2017FY2016FY2015FY2014FY2013
Cash from operations-81.6M-51.5M-37.4M-36.2M-29.8M-37.6M-32.2M-22.5M-27.5M
Capital spending-719.0K-366.0K-166.0K-103.0K0000-12.8M
Free cash flow-82.3M-51.9M-37.5M-36.3M-29.8M-37.6M-32.2M-22.5M-40.3M
Cash from investing-95.2M-366.0K-266.0K-103.0K
Cash from financing11.5M381.2M34.9M2.50M18.8M47.2M54.9M78.7M99.9M
Share buybacks-4.63M-16.2M-6.97M-51.0M-83.7M
Change in cash-165.5M329.4M-2.69M-33.5M-11.5M9.19M-44.1M-32.7M58.7M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 2, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
144 · Notice of proposed saleJun 29, 2026Other filingsSEC
All 158 filings
FilingDateTypeFiled with
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 8, 2026ResultsSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeApr 27, 2026Big-stake noticeSEC
4 · Change in ownershipApr 24, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 21, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
S-3ASR · Registration statementMar 24, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 24, 2026Offer documentSEC
10-K · Annual reportMar 24, 2026Annual reportSEC
8-K · Current reportMar 24, 2026ResultsSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
4 · Change in ownershipFeb 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
8-K · Current reportJan 22, 2026Material contractSEC
424B5 · ProspectusJan 22, 2026Offer documentSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
424B5 · ProspectusJan 20, 2026Offer documentSEC
8-K · Current reportJan 20, 2026Current reportSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
144 · Notice of proposed saleDec 9, 2025Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 4, 2025Other filingsSEC
8-K · Current reportDec 4, 2025Current reportSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
S-3/A · Registration statement, amendedNov 5, 2025Offer documentSEC
S-3/A · Registration statement, amendedNov 5, 2025Offer documentSEC
S-3 · Registration statementOct 2, 2025Offer documentSEC
S-3 · Registration statementOct 2, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
8-K · Current reportJun 4, 2025Current reportSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
ARS · Annual report to shareholdersApr 17, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
10-K · Annual reportMar 20, 2025Annual reportSEC
8-K · Current reportMar 20, 2025ResultsSEC
4/A · Change in ownership, amendedMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4/A · Change in ownership, amendedFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G · Big-stake noticeOct 7, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeOct 4, 2024Big-stake noticeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
SC 13D · Big-stake noticeSep 30, 2024Big-stake noticeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
SEC STAFF LETTERSep 27, 2024Other filingsSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
8-K · Current reportSep 27, 2024Material contractSEC
S-8 · Registration statement for employee plansSep 26, 2024Offer documentSEC
424B4 · ProspectusSep 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 26, 2024Other filingsSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringSep 25, 2024Offer documentSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
CERT · Exchange's certificate of listingSep 25, 2024Other filingsSEC
CORRESP · Letter to the SECSep 25, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 25, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 23, 2024Other filingsSEC
CORRESP · Letter to the SECSep 23, 2024Other filingsSEC
CORRESP · Letter to the SECSep 23, 2024Other filingsSEC
CORRESP · Letter to the SECSep 18, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 18, 2024Other filingsSEC
S-1/A · Registration statement, amendedSep 18, 2024Offer documentSEC
CORRESP · Letter to the SECSep 12, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 6, 2024Other filingsSEC
CORRESP · Letter to the SECSep 3, 2024Other filingsSEC
S-1 · Registration statementSep 3, 2024Offer documentSEC
UPLOAD · Letter from the SECAug 9, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftAug 5, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedAug 5, 2024Offer documentSEC
UPLOAD · Letter from the SECJul 18, 2024Other filingsSEC
DRSLTR · Letter to the SEC with a draftJul 3, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedJul 3, 2024Offer documentSEC
SEC STAFF LETTERJul 2, 2024Other filingsSEC
UPLOAD · Letter from the SECJun 28, 2024Other filingsSEC
DRS · Draft registration statementMay 31, 2024Offer documentSEC
DFeb 13, 2024Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BioAge Labs, Inc.’s releases · as of Jul 31, 2026

Common shares
45,896,909
Fully diluted
45,896,909

Fully diluted

LineSharesAs of
Common shares45,896,909Jul 31, 2026

Share count over time

CountShares
Jul 31, 202645,896,909

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
BlackRock3.54M7.7%US$25.1MSep 30, 2026
a16z Capital Management, L.L.C.3.23M7.0%US$22.9MSep 30, 2026
Vanguard2.33M5.1%US$16.5MSep 30, 2026
Sofinnova Investments, Inc.2.29M5.0%US$16.3MSep 30, 2026
Cormorant Asset Management, LP2.24M4.9%US$15.9MSep 30, 2026
Mpm Bioimpact LLC1.86M4.0%US$13.2MSep 30, 2026
State Street1.35M2.9%US$9.56MSep 30, 2026
Octagon Capital Advisors LP1.3M2.8%US$9.22MSep 30, 2026
D. E. Shaw & Co., Inc.1.16M2.5%US$8.2MSep 30, 2026
Polar Capital Holdings Plc1.07M2.3%US$7.58MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Braidwell LP1.03M2.3%US$7.32MSep 30, 2026
Geode Capital922K2.0%US$6.53MSep 30, 2026
Sands Capital Alternatives, LLC786K1.7%US$5.58MSep 30, 2026
JPMorgan783K1.7%US$5.59MSep 30, 2026
Orbimed Advisors LLC712K1.6%US$5.05MSep 30, 2026
Pivotal bioVenture Partners Investment Advisor LLC653K1.4%US$4.63MSep 30, 2026
Millennium637K1.4%US$4.51MSep 30, 2026
Renaissance Technologies627K1.4%US$4.44MSep 30, 2026
Morgan Stanley532K1.2%US$3.77MSep 30, 2026
Cosmic Management, LLC502K1.1%US$3.56MSep 30, 2026
Dimensional500K1.1%US$3.54MSep 30, 2026
Qube Research & Technologies Ltd484K1.1%US$3.43MSep 30, 2026
Franklin Templeton378K0.82%US$2.25MSep 30, 2026
Nuveen339K0.74%US$2.4MSep 30, 2026
Northern Trust331K0.72%US$2.35MSep 30, 2026
Schwab317K0.69%US$2.25MSep 30, 2026
Y-Intercept (Hong Kong) Ltd317K0.69%US$2.25MSep 30, 2026
Goldman Sachs309K0.67%US$2.19MSep 30, 2026
Yiheng Capital Management, L.P.294K0.64%US$2.08MSep 30, 2026
ADAR1 Capital Management, LLC276K0.60%US$1.96MSep 30, 2026
Comprehensive Financial Management LLC272K0.59%US$1.93MSep 30, 2026
Jacobs Levy Equity Management, Inc264K0.58%US$1.87MSep 30, 2026
UBS253K0.55%US$1.79MSep 30, 2026
Two Sigma222K0.48%US$1.57MSep 30, 2026
Fidelity210K0.46%US$1.49MSep 30, 2026
Sphera Funds Management LTD.183K0.40%US$1.29MSep 30, 2026
AQR Capital Management LLC182K0.40%US$1.29MSep 30, 2026
Acadian Asset Management LLC153K0.33%US$1.08MSep 30, 2026
Man Group plc127K0.28%US$901KSep 30, 2026
Wellington123K0.27%US$875KSep 30, 2026
Ensign Peak Advisors, Inc118K0.26%US$840KSep 30, 2026
BNP Paribas116K0.25%US$823KSep 30, 2026
Schonfeld Strategic Advisors LLC108K0.24%US$767KSep 30, 2026
BNY107K0.23%US$759KSep 30, 2026
Susquehanna102K0.22%US$721KSep 30, 2026
Voleon Capital Management LP101K0.22%US$716KSep 30, 2026
Occudo Quantitative Strategies LP79,6270.17%US$565KSep 30, 2026
Bank of America77,6410.17%US$550KSep 30, 2026
Profund Advisors LLC76,2840.17%US$541KSep 30, 2026
XTX Topco Ltd71,3600.16%US$506KSep 30, 2026

This page holds 50 of 156 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.14M2.5%US$28MJun 30, 2026
iShares Russell 2000 ETF916K2.0%US$22.4MJun 30, 2026
Fidelity Small Cap Index Fund385K0.84%US$3.48MJul 31, 2026
Vanguard Extended Market Index Fund368K0.80%US$9.02MJun 30, 2026
iShares Russell 2000 Value ETF297K0.65%US$7.27MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF262K0.57%US$6.43MJun 30, 2026
iShares Biotechnology ETF223K0.49%US$5.47MJun 30, 2026
Nuveen Quant Small Cap Equity Fund202K0.44%US$1.82MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF171K0.37%US$4.2MJun 30, 2026
Fidelity Extended Market Index Fund156K0.34%US$2.69MMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund155K0.34%US$2.69MMay 31, 2026
Schwab U.S. Small-Cap ETF143K0.31%US$2.47MMay 31, 2026
Franklin Biotechnology Discovery Fund135K0.29%US$1.22MJul 31, 2026
Vanguard U.S. Momentum Factor ETF128K0.28%US$2.21MMay 31, 2026
iShares Micro-Cap ETF118K0.26%US$2.9MJun 30, 2026
Dimensional U.S. Small Cap ETF109K0.24%US$984KJul 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund91,8410.20%US$830KJul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF91,3220.20%US$1.58MMay 31, 2026
Schwab Small-Cap Index Fund85,3890.19%US$772KJul 31, 2026
iShares U.S. Pharmaceuticals ETF82,9380.18%US$2.03MJun 30, 2026
U.S. Small Cap Portfolio81,6560.18%US$738KJul 31, 2026
Master Small Cap Index Series65,7070.14%US$1.61MJun 30, 2026
U.S. Micro Cap Portfolio64,1980.14%US$580KJul 31, 2026
Small Cap Value Fund60,6760.13%US$1.49MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account60,2600.13%US$1.48MJun 30, 2026
Fidelity Total Market Index Fund55,4780.12%US$959KMay 31, 2026
Multi-Manager Small Cap Equity Strategies Fund55,3260.12%US$957KMay 31, 2026
Nuveen Small Cap Blend Index Fund46,5440.10%US$421KJul 31, 2026
Vanguard Explorer Fund45,8760.10%US$415KJul 31, 2026
Fidelity Series Total Market Index Fund45,8620.10%US$793KMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF45,4570.10%US$1.11MJun 30, 2026
Fidelity Small Cap Value Index Fund44,4080.10%US$1.09MJun 30, 2026
JPMorgan Small Cap Value Fund44,3440.10%US$1.09MJun 30, 2026
Avantis U.S. Small Cap Equity ETF43,5260.09%US$753KMay 31, 2026
EQ/2000 Managed Volatility Portfolio38,2100.08%US$937KJun 30, 2026
NVIT Multi-Manager Small Company Fund35,6250.08%US$873KJun 30, 2026
NVIT Small Cap Value Fund33,2760.07%US$816KJun 30, 2026
EQ/Small Company Index Portfolio32,5000.07%US$797KJun 30, 2026
iShares Russell 2000 Growth ETF32,3630.07%US$793KJun 30, 2026
LVIP Franklin Templeton Multi-Factor SMID Cap Equity Fund31,8930.07%US$782KJun 30, 2026
JPMorgan U.S. Small Company Fund30,6810.07%US$752KJun 30, 2026
Nuveen Equity Index Fund27,7560.06%US$251KJul 31, 2026
Dimensional U.S. Core Equity 2 ETF27,7260.06%US$251KJul 31, 2026
Fidelity Nasdaq Composite Index Fund27,4160.06%US$474KMay 31, 2026
LVIP State Street Small-Cap Index Fund25,1000.05%US$615KJun 30, 2026
Ultra-Small Company Fund25,0000.05%US$613KJun 30, 2026
Vanguard Russell 2000 Value Index Fund23,8600.05%US$413KMay 31, 2026
Small Cap Equity Fund23,2980.05%US$571KJun 30, 2026
Fidelity Nasdaq Composite Index ETF20,6750.05%US$357KMay 31, 2026
Schwab Total Stock Market Index Fund19,7140.04%US$178KJul 31, 2026

This page holds 50 of 166 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Barton Shane
Officer: Principal Accounting Officer
Sale20,216USD 25.19US$509KJun 30, 2026
Barton Shane
Officer: Principal Accounting Officer
Sale42,350USD 25.21US$1.07MJun 29, 2026
Rubin Paul D
Officer: Chief Medical Officer
Sale8,820USD 17.81US$157KApr 1, 2026

Big stakes

StakeStakeSharesDateFiling
Kristen Fortney7.20%2.7MDec 31, 2025Schedule 13G
BlackRock, Inc.5.03%2.24MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Healy
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past)
Director · Since at least Sep 25, 2024
Michael Davidson
Other companies: NewAmsterdam Pharma Company N.V. (Chief Executive Officer · Since at least Dec 29, 2023); Tenax Therapeutics, Inc. (Board Director · Since at least Feb 25, 2021); Silence Therapeutics PLC (Director · Jan 2, 2025 – Jan 2, 2025 · Past); Lisata Therapeutics, Inc. (Director · Jul 28, 2020 – Jan 10, 2022 · Past); Omthera Pharmaceuticals Inc (Executive VP & CMO · Apr 11, 2013 – Jul 18, 2013 · Past)
Independent Director · Since at least Mar 26, 2024
Rekha Hemrajani
Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); MaxCyte, Inc. (Non-Executive Director · Since at least Jun 29, 2022); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022)
Independent Director · Since at least Apr 17, 2024
Shane Barton
Other companies: Precision BioSciences, Inc. (VP & Corporate Controller · Jan 1, 2021 – Jun 7, 2023 · Past)
SVP, Finance · Since at least Sep 25, 2024
Vijay Pande
Other companies: Nautilus Biotechnology, Inc. (Director · Jun 14, 2024 – Jun 14, 2024 · Past)
Co-founder & Managing Partner, VZVC · Since at least Sep 25, 2024
Ann NealeChief Development Officer · Since at least Nov 5, 2026
BJ SullivanChief Strategy Officer · Since at least Apr 13, 2026
Chris PatilVP, Media · Since at least Sep 8, 2026
Dov GoldsteinChief Financial Officer · Since at least Apr 24, 2026
Eric MorgenCo-Founder, COO · Since at least Jun 17, 2025
All 25 people
PersonSeat
George HartmanSVP, Chemistry · Since at least Nov 5, 2026
Jean-Pierre GarnierChair of the Board · Since at least Nov 7, 2024
Joseph RodgersVP, Discovery Research · Since at least Nov 5, 2026
Julie GammelgardSVP, People · Since at least Nov 5, 2026
Kevin WilhelmsenVP, Biology · Since at least Nov 5, 2026
Kristen FortneyCo-Founder, CEO · Since at least Sep 8, 2026
Naisha ShahSVP, Data Science · Since at least Nov 5, 2026
Nancy Mitchell-SweeneyVP & Head of Clinical Operations · Since at least Nov 5, 2026
Patrick MartinSVP, Clinical Science · Since at least Nov 5, 2026
Paul RubinCMO & EVP, Research · Since at least Apr 3, 2026
Peng LeongChief Business Officer & Therapeutic Area Head, Brain Aging · Since at least Jun 16, 2026
Rusty MontgomerySVP, Research · Since at least Nov 5, 2026
Sangita GhoshSVP, Technical Operations · Since at least Nov 5, 2026
Yan WangSVP, Translational Aging Biology · Since at least Nov 5, 2026
Yvonne Van GesselVP, Nonclinical Development · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about BioAge Labs, Inc.